NetworkNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT
Post# of 151
(Total Views: 163)
Posted On: 11/11/2022 4:05:00 PM
NetworkNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q3 2022 Financial Report
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, is reporting its financial and operational updates for the third quarter; the quarter ended on Sept. 30, 2022. Included in the report is the fact that the company’s AIMI(TM) platform technology, which is used for diagnosing heart attacks, has been submitted to the U.S Food and Drug Administration (“FDA”) for clearance and the company is on track for initial FDA submission of its AIMIGo(TM) device in the next quarter. Other highlights include that the company broadened its portfolio pipeline during the quarter with its smartwatch connectivity that supports a daily multi-hour heart monitoring solution and received two additional AIMIGo tech patents. Financial numbers reported included R&D expenses for the quarter reaching $1.6 million, compared to $105,000 for Q3 2021; general and administrative expenses for the quarter totaled $2 million and net loss for Q3 was $3.6 million; cash totaled $6.5 million as of the end of September 2022, down from $13.2 million as of Dec. 31, 2021. “Throughout the third quarter we progressed on our commercialization pathway toward a series of important milestones, including the FDA 510(k) application submission of our HeartBeam AIMI product,” said HeartBeam CEO and founder Branislav Vajdic, PhD, in the press release. “We continue to have strong conviction in our HeartBeam AIMI software platform technology and AIMIGo, our end-to-end telemedicine solution, and their potential to offer more accurate heart attack detection and to expedite treatment. As we look toward FDA clearance for HeartBeam AIMI, we are also making significant progress with our core product, the AIMIGo as we prepare for FDA submission in late fourth quarter of this year.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, is reporting its financial and operational updates for the third quarter; the quarter ended on Sept. 30, 2022. Included in the report is the fact that the company’s AIMI(TM) platform technology, which is used for diagnosing heart attacks, has been submitted to the U.S Food and Drug Administration (“FDA”) for clearance and the company is on track for initial FDA submission of its AIMIGo(TM) device in the next quarter. Other highlights include that the company broadened its portfolio pipeline during the quarter with its smartwatch connectivity that supports a daily multi-hour heart monitoring solution and received two additional AIMIGo tech patents. Financial numbers reported included R&D expenses for the quarter reaching $1.6 million, compared to $105,000 for Q3 2021; general and administrative expenses for the quarter totaled $2 million and net loss for Q3 was $3.6 million; cash totaled $6.5 million as of the end of September 2022, down from $13.2 million as of Dec. 31, 2021. “Throughout the third quarter we progressed on our commercialization pathway toward a series of important milestones, including the FDA 510(k) application submission of our HeartBeam AIMI product,” said HeartBeam CEO and founder Branislav Vajdic, PhD, in the press release. “We continue to have strong conviction in our HeartBeam AIMI software platform technology and AIMIGo, our end-to-end telemedicine solution, and their potential to offer more accurate heart attack detection and to expedite treatment. As we look toward FDA clearance for HeartBeam AIMI, we are also making significant progress with our core product, the AIMIGo as we prepare for FDA submission in late fourth quarter of this year.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Heartbeam Inc. (BEAT) Stock Research Links
Scroll down for more posts ▼